Login to Your Account

Clinic Roundup

Thursday, November 17, 2011
• Bionovo Inc., of Emeryville, Calif., reported that the first patient was randomized and will begin dosing in a Phase III pivotal trial evaluating the safety and efficacy of two doses (5 g/day and 10 g/day) of Menerba (MF101) in 1,200 postmenopausal women for the treatment of menopausal hot flashes. Efficacy will be measured by the reduction of moderate to severe hot flushes from baseline to 12 weeks of treatment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription